July 16, 2019
Type C Meeting confirmed that FDA does not believe additional clinical safety, efficacy, or pharmacology studies will be required to support NDA resubmission and review FDA confirmed that the resubmission would be under the current NDA Company accelerates timeline and now expects resubmission of FUROSCIX NDA with the FDA by mid-year 2020 BURLINGTON, Mass., July...


BONESUPPORT HOLDING AB (publ) announces that the patient enrolment schedule for the ongoing FORTIFY study is extended
21. August 2019
Parkinson-symptomer invaderede fra tarmsystemet
Parkinson’s symptoms invade from the gut
18. July 2019
Muslinge-lim som erstatning for operationstråd
Mussel glue to replace surgical sutures
17. July 2019


Lundbeckfonden Ventures

Lundbeckfonden Emerge